PTLA News and Press, Portola Pharmaceuticals Inc. From 12/11/19

While the world of biotech has always been an interesting one, now's an especially exciting time to consider investing in the sector. There are many potential blockbuster drugs awaiting U.S. Food and Drug Administration (FDA) approval, with a number of treatments having already received a thum...

SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refract...

SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with specific subtype...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad hoc quer...

SOUTH SAN FRANCISCO, Calif. , Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine , the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary anticoagulant revers...

CdbMD (NYSEMKT: YCBD ) initiated with Neutral rating and $3.40 (15% downside risk) price target at Cantor Fitzgerald. More news on: cbdMD, Inc., CV Sciences, Inc., Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Investors interested in the exciting world of healthcare have plenty of options to chose from. Whether it be among the many high-growth, small-cap healthcare companies offering cutting-edge treatments or a more established, large-cap giant, the sector is expected to continue to do well as health...

SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will be presented at the 2019 Ame...

The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Portola Pharmaceuticals, Inc. (PTLA) Q3 2019 Earnings Conference Call November 05, 2019 4:30 PM ET Company Participants Jennifer Zibuda – Investor Relations Scott Garland – President and Chief Executive Officer Mardi Dier – Chief Financial and Chief Business ...